Skip to main content

Vera Therapeutics

Vera Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of transformative immunological treatments for serious autoimmune and severe inflammatory diseases, prominently featuring its lead product candidate atacicept for the treatment of IgA nephropathy (Berg's disease). The company conducts advanced clinical trials evaluating targeted biological therapies designed to address the underlying immunological drivers of severe kidney and autoimmune disorders. Its core business operations encompass biopharmaceutical immunology research, clinical trial execution, biologic drug formulation, and commercial pharmaceutical strategy. As a clinical-stage biotechnology enterprise, the company generates minimal commercial revenue and finances its ongoing operational activities through public equity offerings and institutional financing. Vera Therapeutics holds a leading market position in targeted immunology and nephrology therapeutics. The company is headquartered in Brisbane, California, United States, and its common stock trades on the Nasdaq Global Market.

4 of the funds FundTelligence covers report a position in Vera Therapeutics.

Legal name
Vera Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding Vera Therapeutics

Loading...